Latest Intellipharmaceutics International Inc (IPC
Post# of 30
Posted On: 03/12/2014 10:36:14 PM
Latest Intellipharmaceutics International Inc (IPCI) Headlines
IntelliPharmaCeutics (IPCI) Jumps: Stock Up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 7:51AM CDT
IntelliPharmaCeutics International Inc. was a big mover last session, as its shares rose nearly 9% on the day.
5 Stocks Ready for Breakouts
at The Street - Fri Mar 07, 1:19PM CST
These stocks look poised to break out and trade higher from current levels.
Intellipharmaceutics to Present at Two Upcoming Investor Conferences
GlobeNewswire - Tue Mar 04, 4:00PM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that the Company is scheduled to present at the following two upcoming conferences.
Intellipharmaceutics posts higher net loss in 2013
M2 - Wed Feb 19, 6:11AM CST
Canadian pharmaceutical company Intellipharmaceutics International Inc (NasdaqCM:IPCI) (TSX:I) stated on Tuesday a net loss of USD11.5m (USD0.58 per common share) for the year ended 30 November 2013.
Intellipharmaceutics Announces 2013 Year End Results
GlobeNewswire - Tue Feb 18, 6:05AM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the year ended November 30, 2013. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
Biotech News for Advancing Pharma Stocks: Company's Test Results Surpass Expectations For $3.5 Billion ADHD Market
PR Newswire - Tue Feb 04, 8:05AM CST
Market Briefing for leading pharma advancers along with clinical data reveals biotech company is on the verge of fulfilling glaring market need: Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), Pfizer Inc. (NYSE: PFE), IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), Alcobra Ltd. (NASDAQ: ADHD), Horizon Pharma, Inc. (NASDAQ: HZNP) and Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA)
Intellipharmaceutics International Inc awarded first profit-share of USD3.1m from Par Pharmaceuticals Inc for sales of 15 and 30 mg generic Focalin XR
M2 - Tue Feb 04, 4:33AM CST
Pharmaceutical company Intellipharmaceutics International Inc (TSX:I) said on Monday that it has received the first payment of USD3.1m relating to commercial sales of dexmethylphenidate hydrochloride extended-release capsules by its licensee Par Pharmaceutical Inc.
Intellipharmaceutics Receives $3.1 Million From Par Pharmaceuticals, Inc.
GlobeNewswire - Mon Feb 03, 6:00AM CST
- First Profit-Share Payment on 15 and 30 mg Generic Focalin XR(R) Sales
5 Stocks Poised for Breakouts
at The Street - Fri Jan 10, 12:20PM CST
These stocks look ready to break out and trade higher from current levels.
Healthcare Sector Announces Voluntary Recalls, Scheduled Presentations and Offering Programs - Research Report on Baxter, Incyte, Horizon Pharma, POZEN, and IntelliPharmaCeutics
PR Newswire - Mon Dec 02, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Baxter International Inc. (NYSE: BAX), Incyte Corporation (NASDAQ: INCY), Horizon Pharma, Inc. (NASDAQ: HZNP), POZEN Inc. (NASDAQ: POZN), and IntelliPharmaCeutics International Inc. (NASDAQ: IPCI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Intellipharmaceutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Mon Dec 02, 6:00AM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that Shameze Rampertab, Vice President Finance and Chief Financial Officer, will present a Company overview at the 25th Annual Piper Jaffray Healthcare Conference at the New York Palace Hotel in New York at 1:00pm EST on Wednesday, December 4, 2013.
Biotech Stocks Partying Like It's 1999
at The Street - Mon Dec 02, 6:00AM CST
After a weak October, biotech stocks have rebounded in a big way in November. The sector is on pace for an history year of absolute and relative performance.
Intellipharmaceutics International Inc reports 'at-the-market offering' of 5.31m common shares
M2 - Thu Nov 28, 4:54AM CST
Pharmaceutical company Intellipharmaceutics International Inc (NasdaqCM:IPCI) (TSX:I) stated on Wednesday that it plans to sell up to 5,305,484 of its common shares through an 'at-the-market' offering programme.
Intellipharmaceutics Announces At-The-Market Offering of Common Shares
GlobeNewswire - Wed Nov 27, 3:30PM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced an "at-the-market" offering program under which it may from time to time sell up to 5,305,484 of its common shares for up to an aggregate of US$16.8 million through at-the-market issuances on the NASDAQ Capital Market.
Approved Acquisition, FDA Approvals, Senior Note Offerings, and Announcements by Drug Delivery Companies - Research Report on Elan, IntelliPharmaCeutics, Valeant Pharmaceuticals, Hospira, and Alkermes
PR Newswire - Fri Nov 22, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
J.C. Penney, Lowe's, Tesla are big market movers
AP - Wed Nov 20, 3:55PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
Ahead of the Bell: IntelliPharmaCeutics climbs
By The Associated Press - AP - Wed Nov 20, 7:38AM CST
Shares of IntelliPharmaCeutics International Inc. jumped again Wednesday before markets opened, as the generic drug developer continued a strong week that started with a key product approval.
Strength Seen in IntelliPharmaCeutics (IPCI): Stock Shoots 161.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 20, 7:04AM CST
IntelliPharmaCeutics International was a big mover last session, as the company saw its shares shoot by nearly 162% on the day.
HZNP, FB, GRPN and IPCI added to NASDAQ Active Stock Watch List at GSR
ACCESSWIRE - Tue Nov 19, 9:10AM CST
New York, NY - (ACCESSWIRE) - 11/19/2013 - Growing Stock Report initiates its NASDAQ Active Stock Watch List adding Horizon Pharma, Inc. (NASDAQ:HZNP), Facebook, Inc. (NASDAQ:FB), Groupon, Inc. (NASDAQ:GRPN), and IntelliPharmaCeutics International Inc. (NASDAQ:IPCI)
IIROC Trade Resumption - Intellipharmaceutics International Inc.
Newsfile Corp - Tue Nov 19, 7:36AM CST
Trading resumes in:
IntelliPharmaCeutics (IPCI) Jumps: Stock Up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 7:51AM CDT
IntelliPharmaCeutics International Inc. was a big mover last session, as its shares rose nearly 9% on the day.
5 Stocks Ready for Breakouts
at The Street - Fri Mar 07, 1:19PM CST
These stocks look poised to break out and trade higher from current levels.
Intellipharmaceutics to Present at Two Upcoming Investor Conferences
GlobeNewswire - Tue Mar 04, 4:00PM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that the Company is scheduled to present at the following two upcoming conferences.
Intellipharmaceutics posts higher net loss in 2013
M2 - Wed Feb 19, 6:11AM CST
Canadian pharmaceutical company Intellipharmaceutics International Inc (NasdaqCM:IPCI) (TSX:I) stated on Tuesday a net loss of USD11.5m (USD0.58 per common share) for the year ended 30 November 2013.
Intellipharmaceutics Announces 2013 Year End Results
GlobeNewswire - Tue Feb 18, 6:05AM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the year ended November 30, 2013. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
Biotech News for Advancing Pharma Stocks: Company's Test Results Surpass Expectations For $3.5 Billion ADHD Market
PR Newswire - Tue Feb 04, 8:05AM CST
Market Briefing for leading pharma advancers along with clinical data reveals biotech company is on the verge of fulfilling glaring market need: Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), Pfizer Inc. (NYSE: PFE), IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), Alcobra Ltd. (NASDAQ: ADHD), Horizon Pharma, Inc. (NASDAQ: HZNP) and Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA)
Intellipharmaceutics International Inc awarded first profit-share of USD3.1m from Par Pharmaceuticals Inc for sales of 15 and 30 mg generic Focalin XR
M2 - Tue Feb 04, 4:33AM CST
Pharmaceutical company Intellipharmaceutics International Inc (TSX:I) said on Monday that it has received the first payment of USD3.1m relating to commercial sales of dexmethylphenidate hydrochloride extended-release capsules by its licensee Par Pharmaceutical Inc.
Intellipharmaceutics Receives $3.1 Million From Par Pharmaceuticals, Inc.
GlobeNewswire - Mon Feb 03, 6:00AM CST
- First Profit-Share Payment on 15 and 30 mg Generic Focalin XR(R) Sales
5 Stocks Poised for Breakouts
at The Street - Fri Jan 10, 12:20PM CST
These stocks look ready to break out and trade higher from current levels.
Healthcare Sector Announces Voluntary Recalls, Scheduled Presentations and Offering Programs - Research Report on Baxter, Incyte, Horizon Pharma, POZEN, and IntelliPharmaCeutics
PR Newswire - Mon Dec 02, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Baxter International Inc. (NYSE: BAX), Incyte Corporation (NASDAQ: INCY), Horizon Pharma, Inc. (NASDAQ: HZNP), POZEN Inc. (NASDAQ: POZN), and IntelliPharmaCeutics International Inc. (NASDAQ: IPCI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Intellipharmaceutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Mon Dec 02, 6:00AM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that Shameze Rampertab, Vice President Finance and Chief Financial Officer, will present a Company overview at the 25th Annual Piper Jaffray Healthcare Conference at the New York Palace Hotel in New York at 1:00pm EST on Wednesday, December 4, 2013.
Biotech Stocks Partying Like It's 1999
at The Street - Mon Dec 02, 6:00AM CST
After a weak October, biotech stocks have rebounded in a big way in November. The sector is on pace for an history year of absolute and relative performance.
Intellipharmaceutics International Inc reports 'at-the-market offering' of 5.31m common shares
M2 - Thu Nov 28, 4:54AM CST
Pharmaceutical company Intellipharmaceutics International Inc (NasdaqCM:IPCI) (TSX:I) stated on Wednesday that it plans to sell up to 5,305,484 of its common shares through an 'at-the-market' offering programme.
Intellipharmaceutics Announces At-The-Market Offering of Common Shares
GlobeNewswire - Wed Nov 27, 3:30PM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced an "at-the-market" offering program under which it may from time to time sell up to 5,305,484 of its common shares for up to an aggregate of US$16.8 million through at-the-market issuances on the NASDAQ Capital Market.
Approved Acquisition, FDA Approvals, Senior Note Offerings, and Announcements by Drug Delivery Companies - Research Report on Elan, IntelliPharmaCeutics, Valeant Pharmaceuticals, Hospira, and Alkermes
PR Newswire - Fri Nov 22, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
J.C. Penney, Lowe's, Tesla are big market movers
AP - Wed Nov 20, 3:55PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
Ahead of the Bell: IntelliPharmaCeutics climbs
By The Associated Press - AP - Wed Nov 20, 7:38AM CST
Shares of IntelliPharmaCeutics International Inc. jumped again Wednesday before markets opened, as the generic drug developer continued a strong week that started with a key product approval.
Strength Seen in IntelliPharmaCeutics (IPCI): Stock Shoots 161.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 20, 7:04AM CST
IntelliPharmaCeutics International was a big mover last session, as the company saw its shares shoot by nearly 162% on the day.
HZNP, FB, GRPN and IPCI added to NASDAQ Active Stock Watch List at GSR
ACCESSWIRE - Tue Nov 19, 9:10AM CST
New York, NY - (ACCESSWIRE) - 11/19/2013 - Growing Stock Report initiates its NASDAQ Active Stock Watch List adding Horizon Pharma, Inc. (NASDAQ:HZNP), Facebook, Inc. (NASDAQ:FB), Groupon, Inc. (NASDAQ:GRPN), and IntelliPharmaCeutics International Inc. (NASDAQ:IPCI)
IIROC Trade Resumption - Intellipharmaceutics International Inc.
Newsfile Corp - Tue Nov 19, 7:36AM CST
Trading resumes in:
(0)
(0)Intellipharmaceutics International Inc. (IPCIF) Stock Research Links
Scroll down for more posts ▼